Improving Delivery of Healthcare Services for Polysubstance Use NIH HEAL Initiative

Improving Delivery of Healthcare Services for Polysubstance Use NIH HEAL Initiative

One study of 2,016 intoxicated drivers tested for substance use found that 5.6% used both alcohol and cocaine. When taken together, the substances produce cocaethylene (a byproduct of using both cocaine and alcohol) in the body, which plays a role in cocaine-related heart disease and overdoses. The resulting drug intoxication often occurs in patterns, such as cocaine used with alcohol and prescription drugs. Substance use disorders should be evaluated by a psychiatrist, psychologist, or licensed counselor specializing in drug and alcohol addictions. A health professional may utilize blood or urine tests to assess current drug use. However, it is important to note that there is not a lab test that can establish dependence or addiction.

Withdrawal involves experiencing physical, cognitive, and behavioral symptoms due to reducing or halting substance use. To be diagnosed with withdrawal, these symptoms must not be due to another mental disorder or medical condition. supporting those in recovery during the holidays Understanding the severity of a substance use disorder can help doctors and therapists better determine which treatments to recommend. Choosing the appropriate level of care may improve a person’s chances of recovery.

Alcohol is one of the most used drugs, and up to 290 million people have been worldwide diagnosed with alcohol use disorder [67]. Our results are consistent with what has been found in the literature showing that alcohol is frequently used especially with psychostimulants such as cocaine [2,68,69]. A meta-analysis identified that cocaine and alcohol (12% of the population analyzed) were the most common combinations (out of a possible 36 combinations) with a 24–98% range of probabilities for simultaneous use [70] and 37–96% of concurrent cocaine and alcohol use.

  1. A full assessment of both disorders and a treatment plan that takes into account the individual’s medical history, as well as other factors, is necessary for treatment success.
  2. The fact that many (and perhaps most) persons with an OUD use multiple substances (both over their life course and simultaneously in specific drug-using episodes) makes it imperative to learn more about polysubstance use and its consequences [39].
  3. A poly addict is a term that describes a person who has become addicted to taking multiple substances, including prescription drugs, at once.
  4. The possibility of highlighting typical profiles with typical characteristics may have important implications in clinical practice to identify appropriate therapeutic interventions and treatments and improve efficacy.

Substance use can worsen the symptoms of a mental health condition and vice versa, amplifying the effects when taking multiple drugs at once. Symptoms can also occur when taking substances alongside prescription medications for mental health conditions. Finally, people with mental health disorders have been found to have higher rates of substance use and substance use disorders versus the general population. Having a mental disorder can increase the risk for developing multiple substance use disorders.

Opioids are distinct from other rewarding substances through their actions at specific opioid receptors. Studies in animals indicate that activation of μ-opioid receptors on GABA-VTA cells disinhibits DA neurons and increases their activity and DA function in the NAC [67]. When opioid receptors are maximally occupied, the addition of another opioid has no further effect. However, combinations with stimulants that increase synaptic levels of DA or that enhance DA terminal release results in a synergistic effect on DA release that is greater than the effect of either alone [68, 69].

Polysubstance abuse and overdose

If a person needs a higher level of care, ongoing care coordination is often needed as it can be challenging for patients to connect with suitable treatment program(s). The authors thank the research participants enrolled in the Yale-Penn cohort. This study was supported by the National Institutes of Health (R33 DA047527, R21 DC018098, and RF1 MH132337), One Mind, and the VISN 4 Mental Illness Research, Education and Clinical Center at the Crescenz VAMC. The Yale-Penn cohort was supported by multiple grants from the National Institutes of Health (RC2 DA028909, R01 DA12690, R01 DA12849, R01 DA18432, R01 AA11330, R01 AA017535). The funding sources had no role in the design of this study, its execution, analyses, interpretation of the data, and the decision to publish the results. Recovered is not a medical, healthcare or therapeutic services provider and no medical, psychiatric, psychological or physical treatment or advice is being provided by Recovered.

Data and code availability

This research will explore health outcomes of individuals who use drug combinations, particularly those who are treated for one or more substance use disorders. This research will consider the perspectives not only of patients, but also of clinicians, payors, and policy makers. In general, it is recommended to offer medications for ecstasy withdrawal and detox symptoms and timelines each individual substance use disorder in addition to psychosocial support. Per The Department of Veterans Affairs (VA) and the Department of Defense (DoD) SUD treatment guidelines,36 there is insufficient evidence to recommend for or against pharmacotherapy for the treatment of cocaine use disorder or methamphetamine use disorder.

Nicotine activates nicotinic acetylcholine receptors in the VTA, nucleus accumbens, and amygdala, either directly or indirectly, through actions on interneurons. Cannabinoids activate cannabinoid CB1 receptors in the VTA, nucleus accumbens, and amygdala. Cannabinoids facilitate the release of dopamine in the nucleus accumbens through an unknown mechanism either in the VTA or the nucleus accumbens. The blue arrows represent the interactions within the extended amygdala system hypothesized to have a key function in drug reinforcement. The medial forebrain bundle represents ascending and descending projections between the ventral forebrain (nucleus accumbens, olfactory tubercle, septal area) and the ventral midbrain (VTA) (not shown in figure for clarity). AC anterior commissure, AMG amygdala, ARC arcuate nucleus, BNST bed nucleus of the stria terminalis, Cer cerebellum, C-P caudate-putamen, DMT dorsomedial thalamus, FC frontal cortex, Hippo hippocampus, IF inferior colliculus, LC locus coeruleus, LH lateral hypothalamus, N Acc.

Substance-Use vs. Substance-Induced Disorders

They will also ask questions about current and past substance use, including its frequency, amount, and duration. For this reason, a deeper understanding of polysubstance use as a complex pattern is crucial because of its high intrinsic degree of complexity. Polydrug use can be unfavorable to the effectiveness of treatment programs since patients engaging in the use of more drugs simultaneously or concurrently are at increased risk of dropping out [19,20] or less responsive to treatment [21,22,23,24] or more impulsive [25,26]. The nation’s opioid crisis has evolved significantly, now reflecting use of drug combinations, potent synthetic opioids, and stimulants. Toward finding durable solutions to the opioid crisis, research approaches must recognize these shifting patterns of use. With the support and guidance of a professional treatment program, it is possible to overcome a polysubstance use disorder.

Participants were attending government specialist addiction treatment services located in Italy. Subjects entered the treatment pathway after being referred by other services or voluntarily. Once vacancies became available, subjects were provided with an initial psychiatric interview and a second psychological interview for diagnostic purposes.

Share this post